SEC Form 10-Q filed by Ironwood Pharmaceuticals Inc.
$IRWD
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/9/2024 | $5.00 | Market Perform | Leerink Partners |
| 8/8/2024 | $12.00 → $4.00 | Overweight → Equal Weight | CapitalOne |
| 1/17/2024 | $21.00 | Buy | Craig Hallum |
| 12/14/2023 | $20.00 | Overweight | Wells Fargo |
| 11/9/2023 | $21.00 | Buy | Jefferies |
| 9/28/2023 | $22.00 | Mkt Outperform | JMP Securities |
| 9/2/2022 | $15.00 | Overweight | CapitalOne |
| 4/22/2022 | $16.00 | Overweight | Piper Sandler |
– LINZESS® (Iinaclotide) EUTRx prescription demand growth of 13% year-over-year – – Remains on track to complete apraglutide NDA submission in Q1 2025 – – Maintains Full Year 2024 Financial Guidance – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. "LINZESS continued to deliver robust prescription demand growth in the third quarter," said Tom McCourt, chief executive officer of Ironwood Pharmaceuticals. "LINZESS extended units and new-to-brand prescriptions each increased 13% year-over-year, respectively, reinforcing that patients and health care professionals continue to choose
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 7, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, November 7, 2024 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, November 21, 2024. To li
– LINZESS® (linaclotide) EUTRx prescription demand growth of 11% year-over-year – – Plans to pursue apraglutide rolling NDA review; expects to complete submission in the first quarter of 2025 – – On track to deliver CNP-104 topline results in the third quarter of 2024 – – Revises FY 2024 financial guidance due to continued LINZESS pricing pressure associated with higher-than-expected Medicaid utilization trends – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its second quarter 2024 results and recent business performance. "We continued to make progress across our portfolio in the second quarter," said Tom McCourt, chief executive off
Leerink Partners initiated coverage of Ironwood Pharma with a rating of Market Perform and set a new price target of $5.00
CapitalOne downgraded Ironwood Pharma from Overweight to Equal Weight and set a new price target of $4.00 from $12.00 previously
Craig Hallum initiated coverage of Ironwood Pharma with a rating of Buy and set a new price target of $21.00
10-Q - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Friday. Shares of Asana, Inc. (NYSE:ASAN) rose sharply during Friday's session after the company announced a $150 million share repurchase program and reaffirmed its forward guidance. Asana said its board of directors approved a stock repurchase program authorizing the company to repurchase up to $150 million of its Class A common stock through June 30, 2025. Asana shares jumped 13.4% to $12.90 on Friday. Here are some other big stocks recording gains in today’s session. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares jumped 39.2% to $171.89 after the company announced FDA approval of an expansion to
- Form8
New data highlight both stoma and colon-in-continuity (CIC) patients drove the positive primary endpoint with significant relative change from baseline in weekly parenteral support (PS) volume reduction at week 24 Additional secondary endpoints show significant increases in days off PS and clinical responder rates with apraglutide, including achieving enteral autonomy in both stoma and CIC patients – Data from largest GLP-2 Phase III study to date adds to body of evidence on safety and efficacy of once-weekly apraglutide in adults with SBS-IF – New details on safety and tolerability to be presented; showing apraglutide to be well tolerated with a safety profile consistent with previousl
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced the appointment of Sravan K. Emany as senior vice president, chief financial officer. Mr. Emany will become a member of Ironwood's Leadership Team and be responsible for all financial operations of the company, including financial planning and reporting, tax, accounting, and investor relations effective December 6, 2021. He will report to Thomas McCourt, chief executive officer of Ironwood. Mr. McCourt commented, "We always look to our mission to guide our efforts to deliver the highest value to our stakeholders. We believe Sravan's deep financial and corporate strategy capabilities within the he
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced the appointment of John Minardo as senior vice president, chief legal officer. Mr. Minardo will become a member of Ironwood's Leadership Team and oversee the company's Corporate Legal, Compliance and IP teams. He will report to Thomas McCourt, chief executive officer of Ironwood. Mr. McCourt commented, "John's deep legal experience and proven track record, in particular his experience at highly focused healthcare companies, arm him with invaluable expertise that will strongly benefit Ironwood by helping accelerate our business priorities and reinforce our efforts to make a difference for people l
– LINZESS® (Iinaclotide) EUTRx prescription demand growth of 13% year-over-year – – Remains on track to complete apraglutide NDA submission in Q1 2025 – – Maintains Full Year 2024 Financial Guidance – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. "LINZESS continued to deliver robust prescription demand growth in the third quarter," said Tom McCourt, chief executive officer of Ironwood Pharmaceuticals. "LINZESS extended units and new-to-brand prescriptions each increased 13% year-over-year, respectively, reinforcing that patients and health care professionals continue to choose
– New safety and tolerability data show high treatment compliance with apraglutide, low incidence of injection site reactions and adverse events associated with GI tolerability – – Findings reinforce the clinical profile of once-weekly apraglutide; Ironwood expects to complete U.S. regulatory submission in Q1 2025 – – One apraglutide poster recognized as presidential poster recipient – – New linaclotide data shed light on treatment outcomes across patient demographics – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course from subgr
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 7, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, November 7, 2024 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, November 21, 2024. To li